Abstract:In utero hematopoietic cell transplantation (IUHCT) is a nonmyeloablative procedure that leads to donor cell chimerism and donor-specific tolerance. However, most clinical applications of IUHCT have failed because of low levels or even no engraftment of donor cells in immunologically normal fetuses. It is likely that the competition from the host hematopoietic compartment is the primary barrier to successful IUHCT, suggesting that conditioning methods that provide a competitive advantage to donor cells may lead to higher-level engraftment following IUHCT. This study aimed to research whether maternal administration of low-dose total body irradiation (TBI) or busulfan (BU) before IUHCT may result in increased donor cell chimerism in postnatal bone marrow transplantation in a congenic murine model. We first determined the birth and mortality rates after maternal administration of low-dose TBI (0, 2 or 4 Gy) or BU (5, 10, 15, or 20 mg/kg) before IUHCT in B6 mice. The mice that received 2 Gy TBI plus IUHCT showed significantly lower birth rate (23.3%) and a 100% 3-day mortality rate. The mice that received 10 mg/kg BU plus IUHCT had similar birth and 3-day mortality rates (58.6% and 0%) compared to mice that received IUHCT alone (61.1% and 4.55%). We then performed maternal administration of BU at 1 of 3 dosages (5, 10, or 15 mg/kg) at 24 hours before intrauterine transplantation of 2.5 × 105 B6GFP Sca-1+ bone marrow cells (BMCs) or 2.5 × 106 B6GFP BMCs on gestational day 14 (E14). Green fluorescent protein (GFP) chimerism in peripheral blood mononuclear cells (PBMCs), RBCs, and platelets of mice at 4 weeks of age was enhanced significantly with an increase in BU dose. Moreover, GFP chimerism of PBMCs from the B6GFP BMC group was significantly higher than that of the B6GFP Sca-1+ BMC group (22.56% versus 7.20%; P = .018). Finally, the pregnant mice were treated with 10 mg/kg of BU at E13, E14, or E15, followed by intrauterine transplantation of 2.5 × 106 B6GFP BMCs 24 hours later. Except for the short-term level of chimerism in PBMCs, which showed no significant difference among the 3 study groups, the results indicate that both short-term (age 4 weeks) and long-term (age 14 weeks) engraftment in PBMCs, RBCs, and platelets was higher in group E16 compared with groups E14 and E15. We also discovered that the engraftment was stable, multilineage, and increased with time. In conclusion, maternal administration of BU, but not of TBI, along with IUHCT could significantly enhance engraftment in a congenic murine model.

Effects of Chemotherapy on Neuroinflammation, Neuronal Damage, Neurogenesis, and Behavioral Performance in Bone Marrow Transplantation Recipient Mice

[Study on Unrelated Donor Allogeneic Bone Marrow Transplantation with Bu-CY2 Conditioning Regimen for Myelodysplastic Syndrome].

Effects of chimerism on the mice heart transplanted survival with the bone marrow infusion.

Busulfan and Cyclophosphamide for Hemopoietic Stem Cell Transplantation from Related and Unrelated Donors in Patients with Myelodysplastic Syndrome

Effect of Allogeneic Bone Marrow–derived Mesenchymal Stem Cells Transplantation in a Polyi:C-Induced Primary Biliary Cirrhosis Mouse Model

The Effects of Busulfan on Xenogeneic Transplantation of Human Peripheral Blood Mononuclear Cells in Recipient Mice

Experimental Study on Hematopoietic Reconstruction Effects of Peripheral Blood Stem Cells Mobilized by Anti-Cd49d Monoclonal Antibody Plus Rhg-Csf in Mice

Granulocyte colony-stimulating factor increases the therapeutic efficacy of bone marrow mononuclear cell transplantation in cerebral ischemia in mice

Effect of lethal total body irradiation on bone marrow chimerism, acute graft-versus-host disease, and tumor engraftment in mouse models: impact of different radiation techniques using low- and high-energy X-rays

Maternal Administration of Busulfan before in Utero Hematopoietic Cell Transplantation Improves Congenic Bone Marrow Cell Engraftment in a Murine Model

Age and dose dependent changes to the bone and bone marrow microenvironment after cytotoxic conditioning with busulfan

A Novel Bone Marrow Targeted Gadofullerene Agent Protect Against Oxidative Injury in Chemotherapy

Establishment of a Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Model in Mice and Its Related Study

Survival Time of Cardiac Allografts Prolonged by Isogeneic BMT in Mice.

Beneficial Modulatory Effects of Treatment With Bone Marrow Lysate on Hematopoietic Stem Cells and Myeloid Cells in Tumor-Bearing Mice

Effects of short-course immunosuppression on chimerism and tolerance indhuced by bone marrow transplantation without cytoreductive conditioning

Therapeutic Efficacy of Bifidobacterium Longum-Mediated Human Granulocyte Colony-Stimulating Factor And/Or Endostatin Combined with Cyclophosphamide in Mouse-Transplanted Tumors

[Comparison of Acute Graft-Versus-Host Disease Mouse Models Established by TBI and BU/CY Conditioning Regimens]

Allogeneic Compact Bone-Derived Mesenchymal Stem Cell Transplantation Increases Survival of Mice Exposed to Lethal Total Body Irradiation: A Potential Immunological Mechanism

Effect of Danggui Buxue Tang on immunological reconstitution of mice following bone marrow transplantation

[Reduced Intensity of BuCy Conditioning Regimen for Transplantation in the Treatment of Malignant Hematologic Diseases].